HEALTHJun 11 · 14:11 UTCSTAT NEWSMeghana Keshavan

STAT+: Novartis doubles down on molecular glue strategy

Novartis is expanding its molecular glue strategy, Enliven's leukemia drug shows encouraging early data, and SonoThera raised $125 million for an ultrasound-based gene delivery approach. Medicare drug spending is rising faster than expected due to increased GLP-1 medicine use and the Democrats’ Part D redesign.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novartisorganizationmolecular glue strategytopicEnlivenorganizationleukemia drugtopicSonoTheraorganizationMedicareorganizationGLP-1 medicinestopicPart D redesigntopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJun 8 · 12:40 UTC
Incyte strikes up to $2bn deal for blood disorder biotech
HEALTHJun 11 · 12:05 UTC
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
HEALTHJun 1 · 07:02 UTC
Akeso To Boost Manufacturing Of Cancer Drug
HEALTHMay 14 · 11:00 UTC
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
HEALTHMay 29 · 13:34 UTC
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
HEALTHMay 26 · 13:28 UTC
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more